Myeloid-derived Suppressor Cells In Oral Cancer | 28303
Journal of Clinical & Experimental Pathology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Cancer is often associated with destruction in both the humoral and cellular immune responses, and this phenomenon has
been suggested to be attributed by the alteration of several cell populations. A population of CD11b+Gr-1+ cells, one of
the myeloid lineage cells, has been shown to be accumulated within either the tumor microenvironment or peripheral blood
which collates with the impairment of immune response and the promotion of tumor growth. However, this cell type is a
heterogeneous cell population that can be altered by type of the tumor and its anatomical location, and the characterization
of their function during cancer has not been still fully elucidated. Here, we show that CD11b+Gr-1+ cells are increased in the
spleen, bone marrow, peripheral blood and the tumor site in the murine oral squamous cell carcinoma-bearing mice, however,
the phenotype and function of the cells from each origins are not consistent. CD11b+Gr-1+ cells in the tumor site, but not
in the spleen, bone marrow, and peripheral blood exhibit increased expression of PD-L1 on their cell surface and strong
immune suppression against in vitro co-cultured T cells through the expression of PD-L1, indicating that CD11b+Gr-1+ cells
accumulated in tumor bearing host may not be originally immune suppressive, however, they could be phenotypically and
functionally altered by the influence of tumor-derived factors and converted into immune suppressive cells. Our results suggest
that targeting CD11b+Gr-1+ cells would be more efficient strategy for cancer treatment in combination with PD-L1 blocking.
Kei Tomihara received his PhD degree in 2006 from Sapporo Medical University, working on immunegene therapy by adenovirus vector. He then moved to Cancer
Therapy and Research Center (CTRC) at The University of Texas Health Science Center at San Antonio(UTHSCSA) to work with Dr. Shin as a post-doctoral fellow.
He obtained an assistant professor position in 2013 in the Department of Oral and Maxillofacial Surgery Graduate School of Medicine and Pharmaceutical Sciences
for Research, University of Toyama, where he started independent research on cancer immunology.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals